| Name | Title | Contact Details |
|---|
Stealth BioTherapeutics is a privately held biopharmaceutical company committed to bringing mitochondria therapies to patients to treat both common and rare diseases. As a key common element in a variety of serious, debilitating diseases, mitochondria – the cell’s energy source – offer a promising, and yet untapped target to modify diseases with significant unmet treatment needs. Stealth is expanding its clinical development program to additional therapeutic areas, including cardio-renal diseases, ophthalmic disorders and orphan mitochondrial diseases. By defining the broad potential of its mitochondrial platform and therapies, Stealth is leading mitochondrial medicine.
Recognizing the importance of managing a traumatic bleed quickly and effectively, Joe Landolina and Isaac Miller founded Cresilon, Inc. based on the hemostatic plant-based gel technology Joe invented while experimenting in the lab. Cresilon has since grown into a biotechnology company headquartered in Brooklyn, New York, commercializing our medical device technology in the animal health, trauma care, and surgical markets.
Affinivax is a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines designed to induce a broad and robust protective immune response to both disease-relevant polysaccharides and disease-relevant proteins in a single vaccine. Affinivax designs each of its vaccine candidates to optimize the protective immune response to one or both of these antigens utilizing the distinctive plug-and-play nature of its proprietary MAPS™ technology platform, presenting the potential opportunity to make a significant step forward in addressing major healthcare challenges posed by novel and resistant infectious diseases. Affinivax was founded in 2014 with a seed investment from the Bill & Melinda Gates Foundation and an exclusive license to the MAPS technology from Boston Children`s Hospital.
NanoLogix is a biotechnology company specializing in live cell, rapid diagnostics. Our kits are simple and reliable rapid test solutions that detect active threat bacteria and other microorganisms 4x - 12x faster than traditional Petri culture technology, and more cost effectively than PCR Protocol. NanoLogix FlatPack packaging allows for an extended shelf-life that is frequently more than double today's standard. In ongoing shelf-life tests, NanoLogix plates containing TSA media in FlatPacks have maintained nutrient and moisture levels for over two years in cold storage and over one year at room temperature (RT). Other agars have their usable shelf lives extended by varying amounts. NanoLogix plates can be used for isolating microorganisms, total plate count, and for maintaining stock cultures.